Cambridge Healthtech Institute is pleased to introduce its inaugural World Pharma Week Congress 2019 taking place June 17-20 in Boston. Most critical scientifically cutting edge and investment-attractive topics will be discussed at the meeting that includes two well established and two new congresses:

15th Annual Biomarker World Congress
18th Annual World Preclinical Congress
Inaugural Immuno-Oncology Pharma Congress
Inaugural Digital Health Pharma Congress

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.

World Pharma Week is poised to become the leading annual meeting dedicated to all stages of pharmaceutical R&D, from discovery though preclinical development and translational research to clinical biomarkers. With the 15+ year track record, World Pharma Week will deliver a cutting-edge agenda, 1,500+ senior delegates and 130+ exhibitors.

Featured Speakers

Mene Pangalos, PhD
Executive Vice-President, Research & Development, BioPharmaceuticals, AstraZeneca

Jennifer Michaelson, PhD
Vice President, Preclinical Research & Early Development, Cullinan Oncology

Litao Zhang, PhD
Vice President, Leads Discovery and Optimization, Bristol-Myers

Christine Dingivan, PhD
Global Drug Development Head, Data and Digital, Novartis

Michael Woo
Director, Head of Immuno-Oncology Search & Evaluation, External Innovation, EMD Serono, Inc.

Leigh Zawel, PhD
CSO, Cullinan Oncology; Executive Partner, MPM Capital

Emma Lees, PhD
Vice President and Oncology Site Head, Bristol-Myers Squibb

Laszlo Urban, MD, PhD
Global Head, Preclinical Secondary Pharmacology, Novartis Institutes for Biomedical Research

Johan Luthman, PhD
SVP, Neuroscience Clinical Development, Neurology Business Group, Eisai, Inc.

Rakesh Dixit, PhD
President & CEO, Bionavigen

Jonathan Cheng, MD
Vice President & Oncology Therapeutic Area Head, Merck

Holly D. Soares, PhD
Head, Translational Neuroscience, AbbVie